-
Product Insights
New![]()
Croydon CT Generating Station
Croydon CT Generating Station is a thermal project located in Pennsylvania, United States. The project is owned by Constellation Energy Generation LLC. The project came online in 1974. Empower your strategies with our Croydon CT Generating Station report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Company Insights
New![]()
Innovation and Patenting activity of CTS Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CTS Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-996 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-996 in Obesity Drug Details: CT-996 is under development for the treatment of type 2...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-388 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-388 in Obesity Drug Details: CT-388 is under development for the treatment of type-2...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-868 in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-868 in Obesity Drug Details: CT-868 is under development for the treatment of type-2 diabetes,...
-
Company Insights
New![]()
Innovation and Patenting activity of CTS Eventim AG & Co KGaA Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CTS Eventim AG & Co KGaA Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CTS-2016 in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CTS-2016 in Myelodysplastic Syndrome Drug Details: CTS-2016 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-0508 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CT-0508 in Solid Tumor Drug Details:CT-0508 is under development for the treatment of HER2-positive solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-1812 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-1812 in Alzheimer's Disease Drug Details: CT-1812 (CT-018120, Elayta) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-0508 in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CT-0508 in Peritoneal Cancer Drug Details:CT-0508 is under development for the treatment of HER2-positive solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-041 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CT-041 in Pancreatic Cancer Drug Details: CT-041 is under development for the treatment of esophagogastric junction...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-041 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CT-041 in Gastric Cancer Drug Details: CT-041 is under development for the treatment of esophagogastric junction...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-1812 in Geographic Atrophy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-1812 in Geographic Atrophy Drug Details: CT-1812 (CT-018120, Elayta) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-1812 in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-1812 in Alzheimer's Disease Drug Details: CT-1812 (CT-018120, Elayta) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Colorectal Cancer Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Gastric Cancer Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Solid Tumor Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-080 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-080 in Esophageal Cancer Drug Details: CT-080 is under development for the treatment of GCC-positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-023 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-023 in Breast Cancer Drug Details: CT-023 is under development for the treatment of CD19...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-023 in Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CT-023 in Lung Cancer Drug Details: CT-023 is under development for the treatment of CD19...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.